<<Dr. Cramer would like to look at these to determine their general characteristics.... Essentially the question he'd be asking is how pure is the 
fumagillin in the products and what conclusions such an investigation might lead to.>>>

Dr. Sanford - wondering what questions/issues motivated the inquiry? Is there a concern for the veracity of label claims for API, and/or a concern for potency at expiry date, and/or a desire to see if the product is still "good" and can be used (illegally) after expiry? What analytical method would Dr. Cramer use? Is it the same as the one used for the basis of each manufacturers QA/QC and product release, and if not, how would results be interpreted? Nosem-X, previously made by APA in Canada is no longer registered in Canada or the USA that I can see, and Fumidil B does have an NADA in the USA but I am not sure if it is marketed. Fumigillin B is a registered and approved drug in Canada and as such is required to satisfy manufacturing controls addressing potency at manufacture and expiry. Might ask the manufacturer as easily as analyse field samples, but again, just wondering what the motivating questions were.


Greg  Hawkins, DVM
President
CentaurVA Animal Health Inc.
Unit 2, 367 Michener Rd
Guelph, ON Canada  N1K 1E8

(T) +01 519 824 9570 /  800 510 8864 (F) +01 519 824 3553

             ***********************************************
The BEE-L mailing list is powered by L-Soft's renowned
LISTSERV(R) list management software.  For more information, go to:
http://www.lsoft.com/LISTSERV-powered.html

Guidelines for posting to BEE-L can be found at:
http://honeybeeworld.com/bee-l/guidelines.htm